- Home
- CELU vs PLUR Comparison
CELU vs PLUR Comparison
Compare CELU & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELU | PLUR |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 18.5M |
| IPO Year | 2019 | 2001 |
Fundamental Metrics
Financial Performance| Metric | CELU | PLUR |
|---|---|---|
| Price | $1.35 | $0.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 178.9K | 14.3K |
| Earning Date | 09-29-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $26,550,000.00 | $1,016,000.00 |
| Revenue This Year | $165.42 | $902.46 |
| Revenue Next Year | $305.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $0.90 |
| 52 Week High | $2.55 | $4.87 |
Technical Indicators
Market Signals| Indicator | CELU | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | N/A |
| Support Level | $1.11 | N/A |
| Resistance Level | $1.43 | N/A |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 57.58 | 0.00 |
Price Performance
Historical ComparisonAbout CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.